FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways

por Rabik, Cara A., Wang, Jiawan, Pratilas, Christine A.
Publicado 2020

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice

por Annesley, Colleen E., Rabik, Cara, Duffield, Amy S., Rau, Rachel E., Magoon, Daniel, Li, Li, Huff, Vicki, Small, Donald, Loeb, David M., Brown, Patrick
Publicado 2018

Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated

por Stevens, Alexandra McLean, Schafer, Eric S., Li, Minhua, Terrell, Maci, Rashid, Raushan, Paek, Hana, Bernhardt, Melanie B., Weisnicht, Allison, Smith, Wesley T., Keogh, Noah J., Alozie, Michelle C., Oviedo, Hailey H., Gonzalez, Alan K., Ilangovan, Tamilini, Mangubat-Medina, Alicia, Wang, Haopei, Jo, Eunji, Rabik, Cara A., Bocchini, Claire, Hilsenbeck, Susan, Ball, Zachary T., Cooper, Todd M., Redell, Michele S.
Publicado 2023

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium

por Stefanski, Heather E., Eaton, Anne, Baggott, Christina, Rossoff, Jenna, Verneris, Michael R., Prabhu, Snehit, Pacenta, Holly L., Phillips, Christine L., Talano, Julie-An, Moskop, Amy, Margossian, Steven P., Myers, Gary Douglas, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, M. Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Fabrizio, Vanessa A., Chinnabhandar, Vasant, Goksenin, A. Yasemin, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M.
Publicado 2022

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report

por Fabrizio, Vanessa A., Phillips, Christine L., Lane, Adam, Baggott, Christina, Prabhu, Snehit, Egeler, Emily, Mavroukakis, Sharon, Pacenta, Holly, Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Moskop, Amy, Margossian, Steven P., Verneris, Michael R., Myers, Gary Douglas, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Chinnabhandar, Vasant, Kunicki, Michael, Goksenin, A. Yasemin, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M.
Publicado 2022

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia

por Moskop, Amy, Pommert, Lauren, Baggott, Christina, Prabhu, Snehit, Pacenta, Holly L., Phillips, Christine L., Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Margossian, Steve P., Verneris, Michael R., Myers, G. Doug, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle L., Satwani, Prakash, Krupski, Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Fabrizio, Vanessa A., Chinnabhandar, Vasant, Goksenin, A. Yasemin, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Guest, Erin M., Breese, Erin H., Schultz, Liora M.
Publicado 2022

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

por Fabrizio, Vanessa A., Boelens, Jaap Jan, Mauguen, Audrey, Baggott, Christina, Prabhu, Snehit, Egeler, Emily, Mavroukakis, Sharon, Pacenta, Holly, Phillips, Christine L., Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Moskop, Amy, Margossian, Steven P., Verneris, Michael R., Myers, Gary Douglas, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Chinnabhandar, Vasant, Kunicki, Michael, Goksenin, A. Yasemin, Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M., Curran, Kevin J.
Publicado 2022